Role of the bed nucleus of the stria terminalis in the cardiovascular responses to acute restraint stress in rats.
The aim of this work was to test the hypothesis that the bed nucleus of the stria terminalis (BST) and noradrenergic neurotransmission therein mediate cardiovascular responses to acute restraint stress in rats. Bilateral microinjection of the non-specific synaptic blocker CoCl(2) (0.1 nmol/100 nl) into the BST enhanced the heart rate (HR) increase associated with acute restraint without affecting the blood pressure increase, indicating that synapses within the BST influence restraint-evoked HR changes. BST pretreatment with the selective alpha(1)-adrenoceptor antagonist WB4101 (15 nmol/100 nl) caused similar effects to cobalt, indicating that local noradrenergic neurotransmission mediates the BST inhibitory influence on restraint-related HR responses. BST treatment with equimolar doses of the alpha(2)-adrenoceptor antagonist RX821002 or the beta-adrenoceptor antagonist propranolol did not affect restraint-related cardiovascular responses, reinforcing the inference that alpha(1)-adrenoceptors mediate the BST-related inhibitory influence on HR responses. Microinjection of WB4101 into the BST of rats pretreated intravenously with the anticholinergic drug homatropine methyl bromide (0.2 mg/kg) did not affect restraint-related cardiovascular responses, indicating that the inhibitory influence of the BST on the restraint-evoked HR increase could be related to an increase in parasympathetic activity. Thus, our results suggest an inhibitory influence of the BST on the HR increase evoked by restraint stress, and that this is mediated by local alpha(1)-adrenoceptors. The results also indicate that such an inhibitory influence is a result of parasympathetic activation.
Department of Pharmacology, School of Medicine of Ribeirão Preto, University of São Paulo, RibeirãoPreto, São Paulo, Brazil.
C C
CC
Crestani
F H F
FH
Alves
R F
RF
Tavares
F M A
FM
Corrêa
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002319:Cardiovascular System / Q000503:physiopathology*; D003035:Cobalt / Q000494:pharmacology; D004146:Dioxanes / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects*; D019329:Idazoxan / Q000031:analogs & derivatives / Q000494:pharmacology; D008297:Male; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018340:Receptors, Adrenergic, alpha-1 / Q000502:physiology*; D012149:Restraint, Physical; D013315:Stress, Psychological / Q000503:physiopathology*; D009435:Synaptic Transmission; D013787:Thalamic Nuclei / Q000187:drug effects / Q000502:physiology*; D014326:Tropanes / Q000494:pharmacology
D004146:Dioxanes; D018340:Receptors, Adrenergic, alpha-1; D014326:Tropanes; D003035:Cobalt; C100236:homatropine; D011433:Propranolol; C058525:2-methoxyidazoxan; C010654:(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane; C018021:cobaltous chloride; D019329:Idazoxan